Jefferies Financial Group Comments on Replimune Group, Inc.’s Q2 2023 Earnings (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPLGet Rating) – Analysts at Jefferies Financial Group issued their Q2 2023 earnings estimates for shares of Replimune Group in a research note issued to investors on Thursday, May 19th. Jefferies Financial Group analyst R. Song forecasts that the company will earn ($0.67) per share for the quarter. Jefferies Financial Group also issued estimates for Replimune Group’s Q3 2023 earnings at ($0.69) EPS and FY2027 earnings at $0.29 EPS.

A number of other analysts have also commented on the stock. JPMorgan Chase & Co. reduced their price target on shares of Replimune Group from $47.00 to $39.00 and set an “overweight” rating for the company in a research note on Monday, April 4th. BMO Capital Markets reduced their price target on shares of Replimune Group from $51.00 to $30.00 and set an “outperform” rating for the company in a research note on Friday, March 18th. SVB Leerink reduced their price target on shares of Replimune Group from $49.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday. Piper Sandler reduced their price target on shares of Replimune Group from $52.00 to $44.00 in a research note on Thursday. Finally, Zacks Investment Research upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, May 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average target price of $46.83.

NASDAQ:REPL opened at $14.79 on Monday. The firm has a market cap of $698.24 million, a P/E ratio of -6.54 and a beta of 2.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 23.39 and a current ratio of 23.39. Replimune Group has a fifty-two week low of $13.05 and a fifty-two week high of $40.22. The firm has a 50-day simple moving average of $16.74 and a two-hundred day simple moving average of $21.50.

In other Replimune Group news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of Replimune Group stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $15.42, for a total transaction of $254,430.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $14.59, for a total transaction of $140,530.88. Following the transaction, the chief executive officer now directly owns 1,401,080 shares in the company, valued at approximately $20,441,757.20. The disclosure for this sale can be found here. In the last three months, insiders sold 39,399 shares of company stock worth $588,526. 40.30% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new stake in shares of Replimune Group during the third quarter valued at approximately $108,000. Royal Bank of Canada raised its position in shares of Replimune Group by 15.8% during the third quarter. Royal Bank of Canada now owns 4,804 shares of the company’s stock valued at $143,000 after buying an additional 657 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Replimune Group by 455.1% during the third quarter. BNP Paribas Arbitrage SA now owns 5,601 shares of the company’s stock valued at $166,000 after buying an additional 4,592 shares during the last quarter. PDT Partners LLC bought a new stake in shares of Replimune Group during the first quarter valued at approximately $185,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Replimune Group during the third quarter valued at approximately $217,000. 75.42% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile (Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Featured Stories

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.